ASTRAZENICA
July 1st, 2003
BY KEITH NUTHALLASTRAZENICA has been formally accused by the European Commission of illegally manipulating European patent laws, to delay the marketing of generic versions of its top selling acid disease drug Losec; in a formal Statement of Objections following an anti-trust inquiry, Brussels claims the Anglo-Swedish group misled EU national patent offices about the earliest date it secured marketing authorisation for the drug in any Member State. By doing so, it secured longer supplementary protection certificates, blocking generic competitors for longer than it ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.